A phase II, open-label study of PTK787/ZK222584 [vatalanib] in the treatment of metastatic gastrointestinal stromal tumors (GISTs) resistant to imatinib mesylate
Phase of Trial: Phase II
Latest Information Update: 02 Jun 2011
At a glance
- Drugs Vatalanib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Therapeutic Use
- 07 Nov 2007 Status changed from recruiting to completed as identified from clinicaltrials.gov website.
- 01 Nov 2005 New trial record.